Attralus Therapeutics
Nicolas Angell has worked in the pharmaceutical industry since 1990. Nicolas'swork experience includes positions at Glaxo as a Research Scientist (1990-1995), Merck as a Research Scientist (1995-2000), Pacific Northwest National Laboratory as a Postdoctoral Research Fellow (2000-2002), Human Genome Sciences or HGSI as a Senior Scientist in the Pharmaceutical Sciences, Protein Development Department (2002-2004), and Amgen as a Senior Scientist in the Analytical Sciences, Process & Analytical Sciences (2004-2021). Nicolas then moved to Connect Biopharma as an Executive Director of CMC Project Management & Strategic Alliance (2021-2022). Currently, they are an Executive Director of Analytical and Formulation Development at Attralus (2022-present).
Nicolas Angell obtained a PhD in Chemistry from Imperial College London between 1997 and 2000.
This person is not in any offices
Attralus Therapeutics
Attralus is a clinical stage biopharmaceutical company focused on creating transformative medicines to improve the lives of patients with systemic amyloidosis.